Evaluation of endocrine changes in women with the polycystic ovary syndrome during metformin treatment
Open Access
- 20 August 2013
- journal article
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
- Vol. 13 (3) , 180-185
Abstract
The aim of study was to evaluate endocrine changes in PCOS women during metformin treatment. One hundred women with PCOS, aged 20-40 years were included. A complete hormonal and metabolic pattern was recorded for each subject every 6 months. Metformin treatment after 6 and 12 months significantly reduced weight, BMI, waist circumference, insulin and HOMA-IR (p=0.000) with high differences of variances within repeated measurements. There was significant reduction of PRL, testosterone and estradiol (p=0.000) with small differences within repeated measurements. Metformin did not have effect on TSH. However, results showed important reduction of CRP, LH, LH/FSH, androstendione, DHEA-S and progesterone (p=0.000) with moderate differences within measures. Metformin restored menstrual cyclicity in most participants. At baseline in study group was 69% women with oligomenorrhoea, amenorrhoea or polymenorrhoea. After 12 months of treatment, only 20% PCOS women had irregular menstrual cycle (p=0.000). Hirsutism was also reduced. Intriguingly, during first 6 months of treatment in PCOS women 9 pregnancies occurred (p=0.000), while during last 6 months treatment were 2 pregnancies (p=0.317), in total 11(13%). Multiple regression model revealed that the presence of anovulation in PCOS women was strongly associated with BMI, waist, FSH and age. Insulin resistance was significantly predicted by BMI, cholesterol, progesterone and presence of hirsutism. The metformin therapy significantly improved insulin resistance, imbalance of endocrine hormones, hirsutism and menstrual cyclicity in women with PCOS. The most important predictors for duration of metformin treatment in PCOS women were testosterone, progesterone, FSH, CRP and presence of anovulation.Keywords
This publication has 30 references indexed in Scilit:
- State of the Art Review: Emerging Therapies: The Use of Insulin Sensitizers in the Treatment of Adolescents with Polycystic Ovary Syndrome (PCOS)International Journal of Pediatric Endocrinology, 2011
- Thyroidal effect of metformin treatment in patients with polycystic ovary syndromeClinical Endocrinology, 2011
- Metformin decreases IGF1-induced cell proliferation and protein synthesis through AMP-activated protein kinase in cultured bovine granulosa cellsReproduction, 2010
- Meta-analysis: Metformin Treatment in Persons at Risk for Diabetes MellitusThe American Journal of Medicine, 2008
- Metformin for the Treatment of the Polycystic Ovary SyndromeNew England Journal of Medicine, 2008
- POSITION STATEMENT: Glucose Intolerance in Polycystic Ovary Syndrome—A Position Statement of the Androgen Excess SocietyThe Journal of Clinical Endocrinology & Metabolism, 2007
- Ovarian size and blood flow in women with polycystic ovary syndrome and their correlations with endocrine parametersFertility and Sterility, 2005
- Improving reproductive performance in overweight/obese women with effective weight managementHuman Reproduction Update, 2004
- The Anti-diabetic Drugs Rosiglitazone and Metformin Stimulate AMP-activated Protein Kinase through Distinct Signaling PathwaysJournal of Biological Chemistry, 2002
- Regulation of Gonadotropin Secretion: Implications for Polycystic Ovary SyndromeSeminars in Reproductive Medicine, 2002